Second Generation Antipsychotic-Induced Obsessive-Compulsive Symptoms in Schizophrenia: A Review of the Experimental Literature
The DOI matches its Crossref record; 185 of the 186 references it cites were found in a registry or an index.
Abstract
Second generation antipsychotics (SGAs) have been implicated in the de novo emergence and exacerbation of obsessive-compulsive symptoms (OCS) in patients with schizophrenia. Among SGAs, clozapine, olanzapine, and risperidone are the most prominent agents associated with these sequelae, according to case reports. Comorbid OCS can impede recovery by compromising treatment benefits, medication compliance, and clinical prognoses. Previous reviews of SGA-induced OCS have predominantly focused on descriptive case reports, with limited attention paid toward experimental findings. To address this paucity of data, we sought to review the effects of SGAs on OCS in schizophrenia in the experimental literature, while addressing the role of different treatment (duration, dose, serum levels) and pharmacogenetic factors. Our findings suggest that clozapine confers the greatest risk of OCS in schizophrenia, with 20 to 28% of clozapine-treated patients experiencing de novo OCS, in addition to 10 to 18% incurring an exacerbation of pre-existing OCS. Clozapine can also yield full threshold obsessive-compulsive disorder (OCD), in some cases. Olanzapine is another high risk drug for secondary OCS which occurs in 11 to 20% of schizophrenic patients receiving olanzapine therapy. At this time, there is insufficient experimental evidence to characterize the effects of other SGAs on OCS. Despite some experimental support for the involvement of longer treatment duration and genetic factors in mediating drug-induced OCS, more research is needed to clearly elucidate these associations. Based on these results, schizophrenic patients should be routinely monitored for OCS throughout the course of SGA treatment, particularly when clozapine or olanzapine is administered.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“despite the potential link of these medications with the occurrence of obsessive-compulsive symptoms.59”
From Cognitive Inflexibility Shares Across Schizophrenia and Obsessive-Compulsive Disorder: A Task-Based Functional MRI Study (2025) · cites this paper as [59]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Diagnostic and Statistical Manual of Mental Disorders, 5th ed.
Carter, M. J. (2014) · Therapeutic Recreation Journal · Cited by 15,169
J Neuropsychiatry Clin Neurosci
Yudofsky, S. C., & Hales, R. E. (1992) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.4.4.359 · Cited by 3,818
The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication
Ruscio, A. M., Stein, D. J., Chiu, W. T., & Kessler, R. C. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.94 · Cited by 2,771
Genome-wide association analysis identifies 13 new risk loci for schizophrenia
Multicenter Genetic Studies of Schizophrenia Consortium, Ripke, S., Psychosis Endophenotypes International Consortium, Wellcome Trust Case Control Consortium 2, O'Dushlaine, C., Chambert, K., Moran, J. L., Kähler, A. K., Akterin, S., Bergen, S. E., et al. (2013) · Nature Genetics · doi:10.1038/ng.2742 · Cited by 1,496
The Epidemiology of Obsessive-Compulsive Disorder in Five US Communities
Karno, M. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800360042006 · Cited by 1,351
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
(2007) · PubMed · Cited by 953
(2008) · Cited by 889
Research works printed but not linked: 1
- Aggarwal A, Sharma D, Sharma R, Kumar R. Obsessive-compulsive symptoms following clozapine administration. Prim Psychiatry. 2010;17(3):58–9.
Cited by
The neural underpinnings of cognitive flexibility and their disruption in psychotic illness
Waltz, J. A. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2016.06.005 · Cited by 122
“…picture suggests that increasing available serotonin (through SSRI administration), can be used to successfully reduce compulsivity (Goddard et al., 2008), whereas reducing 5HT transmission, with 5HT receptor antagonists, can induce compulsivity (Schirmbeck et al., 2013, Fonseka et al., 2014).”
BackgroundTreatment-resistant OCD: Pharmacotherapies in adults
van Roessel, P., Grassi, G., Aboujaoude, E. N., Menchón, J. M., Ameringen, M. V., & Rodríguez, C. I. (2022) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2022.152352 · Cited by 112
Zike, I. D., Xu, T., Hong, N., & Veenstra-VanderWeele, J. M. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.09.012 · Cited by 87
“…system may be a way to reveal the worsened symptoms that have been reported with certain drugs in OCD patients, including clozapine, stimulants, and sumatriptan and its analogs (Broocks et al., 1998, Koran et al., 2001b, Gross-Isseroff et al., 2004, Bloch et al., 2009, Fonseka et al., 2014).”
BackgroundResultPampaloni, I., Marriott, S., Pessina, E., Fisher, C., Govender, A., Mohamed, H., Chandler, A., Tyagi, H., Morris, L., & Pallanti, S. (2022) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2022.152342 · Cited by 107
Obsessive–compulsive disorder comorbid with schizophrenia and bipolar disorder
Reddy, Y. C. J., & Sharma, L. (2019) · Indian Journal of Psychiatry · doi:10.4103/psychiatry.indianjpsychiatry_527_18 · Cited by 84
“Clozapine is most frequently associated with exacerbation of or de novo emergence of OCS in schizophrenia,[44,46,47] although there are few contrary reports.”
BackgroundResult
Metadata
- Authors
- Fonseka, T. M., Richter, M. A., & Müller, D. J.
- Affiliations
- Centre for Addiction and Mental Health (CA)
- Sunnybrook Health Science Centre (CA)
- Corresponding author
- Müller, Daniel J.
- Venue
- Current Psychiatry Reports
- Published
- 2014-09-26
- Volume
- 16
- Issue
- 11
- Pages
- 510-510
- ISSN
- 1523-3812 (ISSN-L)
- 1535-1645
- OpenAlex
- W2002363278
- Cited by
- 93
- References
- 186
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 9 · 2023: 9 · 2022: 10 · 2021: 7 · 2020: 9 · 2019: 5 · 2018: 9 · 2017: 4 · 2016: 9 · 2015: 5
- FWCI
- 0.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Current Psychiatry Reports (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
- Keywords
- atypical antipsychotics, obsessive-compulsive symptoms, schizophrenia, clozapine, olanzapine, risperidone, pharmacogenetics, treatment duration, serum drug concentration, adverse drug reactions, symptom exacerbation
- MeSH terms
- Humans, Obsessive-Compulsive Disorder, Schizophrenia, Antipsychotic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Second Generation Antipsychotic-Induced Obsessive-Compulsive Symptoms in Schizophrenia: A Review of the Experimental Literature. https://app.cochat.ai/papers/10.1007/s11920-014-0510-8
- The paper
- Fonseka, T. M., Richter, M. A., & Müller, D. J. (2014). Second Generation Antipsychotic-Induced Obsessive-Compulsive Symptoms in Schizophrenia: A Review of the Experimental Literature. Current Psychiatry Reports. https://doi.org/10.1007/s11920-014-0510-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.